Overview
Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening represents a transformative approach for enhancing drug delivery to the brain in Alzheimer's disease. This category page catalogs companies developing focused ultrasound technologies — particularly MRI-guided focused ultrasound (MRgFUS) — to transiently and reversibly open the BBB, enabling therapeutics that would otherwise be excluded from the central nervous system to reach their targets.
The technology uses focused acoustic energy combined with microbubble contrast agents to mechanically open tight junctions between endothelial cells, allowing antibodies, enzymes, gene therapies, and other large molecules to enter the brain parenchyma. This approach has shown promise in clinical trials for enhancing delivery of [anti-amyloid antibodies](/companies/ad-pipeline-companies) and other disease-modifying therapies[@shoesmith2022].
Key Companies and Technologies
Insightec (ExAblate Neuro)
Insightec is the leading company in focused ultrasound technology, with the ExAblate Neuro platform — the first and only FDA-approved MRI-guided focused ultrasound system[@insightec2024]:
| Attribute | Details |
|-----------|---------|
| Headquarters | Haifa, Israel |
| Founded | 1999 |
| Key Product | ExAblate Neuro |
| Platform | MRI-guided focused ultrasound (MRgFUS) |
| Regulatory Status | FDA approved for ET and PD tremor; Investigational for BBB opening |
...Overview
Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening represents a transformative approach for enhancing drug delivery to the brain in Alzheimer's disease. This category page catalogs companies developing focused ultrasound technologies — particularly MRI-guided focused ultrasound (MRgFUS) — to transiently and reversibly open the BBB, enabling therapeutics that would otherwise be excluded from the central nervous system to reach their targets.
The technology uses focused acoustic energy combined with microbubble contrast agents to mechanically open tight junctions between endothelial cells, allowing antibodies, enzymes, gene therapies, and other large molecules to enter the brain parenchyma. This approach has shown promise in clinical trials for enhancing delivery of [anti-amyloid antibodies](/companies/ad-pipeline-companies) and other disease-modifying therapies[@shoesmith2022].
Key Companies and Technologies
Insightec (ExAblate Neuro)
Insightec is the leading company in focused ultrasound technology, with the ExAblate Neuro platform — the first and only FDA-approved MRI-guided focused ultrasound system[@insightec2024]:
| Attribute | Details |
|-----------|---------|
| Headquarters | Haifa, Israel |
| Founded | 1999 |
| Key Product | ExAblate Neuro |
| Platform | MRI-guided focused ultrasound (MRgFUS) |
| Regulatory Status | FDA approved for ET and PD tremor; Investigational for BBB opening |
Technology: The ExAblate Neuro system uses a 1,024-element phased array transducer with real-time MRI thermometry for precise targeting. For BBB opening, low-intensity ultrasound combined with intravenous microbubbles transiently opens the barrier[@exablate].
AD Clinical Programs:
- Blood-brain barrier opening in AD patients: Multiple clinical trials completed showing safety and preliminary efficacy
- Hippocampal targeting: Opening BBB in hippocampus region critical for memory[@rezaifus2020]
- Amyloid plaque reduction: Demonstrated significant plaque reduction when combined with BBB opening[@dhaese2022]
- Partnerships: Collaborations with pharmaceutical companies for enhanced antibody delivery
Cross-References:
- [Insightec](/companies/insightec) — Company page
- [Focused Ultrasound BBB Opening](/therapeutics/focused-ultrasound-bbb-opening) — Mechanism page
CarThera (SonoCloud)
CarThera is a French medical technology company developing the SonoCloud implantable ultrasound device for repeated BBB opening[@carthera2024]:
| Attribute | Details |
|-----------|---------|
| Headquarters | Paris, France |
| Founded | 2010 |
| Key Product | SonoCloud |
| Platform | Implantable ultrasound emitter |
| Stage | Phase I/II clinical trials |
Technology: Unlike external FUS systems, SonoCloud is a cranial implant that emits ultrasound through a small craniotomy. This allows for repeated, controlled BBB opening sessions without repositioning the patient[@carpentier2016].
Advantages:
- Repeat treatments: Enables multiple treatment sessions for chronic conditions like AD
- Lower cost per treatment: After initial implantation
- Consistent targeting: Fixed positioning ensures accuracy
- Potential for chronic delivery: Can be combined with ongoing drug therapy
Clinical Applications:
- Glioblastoma: Most advanced program, demonstrating safety
- Alzheimer's disease: Investigational, focusing on amyloid reduction
- Combination with immunotherapy: Enhanced checkpoint inhibitor delivery
Cross-References:
- [CarThera](/companies/carthera) — Company page (if exists)
- [Focused Ultrasound for Brain Tumors](/therapeutics/focused-ultrasound)
Emerging Players
The focused ultrasound BBB opening space is attracting additional companies and research groups:
NaviFUS
- Focus: MRI-guided focused ultrasound systems
- Origin: Academic spinout from medical ultrasound research
- Stage: Preclinical/research phase
BrainSonix
- Focus: Non-invasive neuromodulation via focused ultrasound
- Approach: Low-intensity FUS for BBB modulation
- Stage: Discovery
Cerebrotech
- Focus: MRI-based focused ultrasound for brain disorders
- Technology: MR-guided therapeutic ultrasound
- Stage: Preclinical
>
Note: These are emerging companies/institutions. If detailed company pages exist, they will be linked here.
Technology Comparison
| Company | Device | Invasiveness | Reusability | Target | AD Status |
|---------|--------|--------------|-------------|--------|----------|
| Insightec | ExAblate Neuro | Non-invasive | Multiple sessions | Any brain region | Phase I/II |
| CarThera | SonoCloud | Minimally invasive (implant) | Chronic treatments | Local region | Investigational |
| NaviFUS | Research system | Non-invasive | Multiple sessions | Research | Preclinical |
| BrainSonix | FUS device | Non-invasive | Multiple sessions | Research | Discovery |
| Cerebrotech | MR-guided FUS | Non-invasive | Multiple sessions | Research | Preclinical |
Mechanism of Action
Mermaid diagram (expand to render)
Key Steps
Microbubble Administration: Intravenous injection of lipid-shelled microbubbles (1-5 μm diameter)[@shoesmith2022]
MRI-Guided Targeting: Precise focus on target brain region
Cavitation Induction: Acoustic pressure causes microbubble oscillation
Tight Junction Disruption: Mechanical forces open endothelial junctions
Drug Delivery: Therapeutics enter brain tissue
Barrier Restoration: Junctions reform within 6-24 hours
Clinical Trial Landscape
| Company | Indication | Phase | Status | Key Findings |
|---------|------------|-------|--------|--------------|
| Insightec | AD (BBB opening + antibodies) | Phase I | Completed | Safe BBB opening; enhanced antibody delivery[@lipsman2018] |
| Insightec | AD (hippocampal BBB) | Phase I | Completed | Sustained opening; no serious AEs[@rezaifus2020] |
| Insightec | AD (amyloid reduction) | Phase I/II | Completed | Significant plaque reduction[@dhaese2022] |
| CarThera | Glioblastoma | Phase I/II | Active | Safety established |
| CarThera | AD | Planning | Preclinical | - |
Therapeutic Synergies
FUS + Anti-Amyloid Antibodies
Focused ultrasound BBB opening dramatically enhances delivery of monoclonal antibodies[@shoesmith2022]:
| Antibody | Without FUS | With FUS | Enhancement |
|----------|-------------|----------|-------------|
| Aduhelm (aducanumab) | Limited brain penetration | 10-50x increase | 10-50x |
| Leqembi (lecanemab) | Partial delivery | Enhanced plaque binding | 5-20x |
| Donanemab | Restricted distribution | Improved tau clearance | 5-15x |
Clinical Implication: FUS may enable:
- Dose reduction: Lower antibody doses for equivalent effect
- Improved efficacy: More complete target engagement
- Better outcomes: Enhanced amyloid/tau clearance
FUS + Gene Therapy
- AAV vectors (>70 nm) normally excluded by BBB
- FUS enables 10-50x enhancement in non-human primates
- Potential for CRISPR-Cas9 delivery
FUS + Chemotherapy
- Temozolomide: 5-10x increase in brain concentration
- Doxorubicin: Significant BBB penetration
Scientific Rationale
Why FUS BBB Opening Matters for AD
Large molecule delivery: Antibodies (~150 kDa), enzymes, siRNAs cannot cross BBB by passive diffusion
Genetic targets: AD-relevant genes (APP, APOE, TREM2) require gene-silencing approaches
Disease modification: Targets inside neurons require intracellular delivery
Combination therapies: Multiple mechanisms may require simultaneous CNS deliveryClinical Evidence Summary
| Study | N | Key Finding | Reference |
|-------|---|-------------|-----------|
| Lipsman et al. | 5 AD | Safe BBB opening in hippocampus | [@lipsman2018] |
| Rezai et al. | 9 AD | Sustained BBB opening; no serious AEs | [@rezaifus2020] |
| D'Haese et al. | 12 AD | Significant amyloid plaque reduction | [@dhaese2022] |
Cross-Links
- [Focused Ultrasound BBB Opening](/therapeutics/focused-ultrasound-bbb-opening)
- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
- [AD BBB Modulation Companies](/companies/ad-bbb-modulation-transport-companies)
- [AD Pipeline Companies](/companies/ad-pipeline-companies)
- [AD Neurovascular Therapy Companies](/companies/ad-neurovascular-cerebral-vasculature-therapy-companies)
- [Insightec](/companies/insightec)
- [CarThera](/companies/carthera)
- [Focused Ultrasound](/technologies/focused-ultrasound-neuromodulation)
References
[Insightec Company Overview (2024)](https://www.insightec.com/)
[ExAblate Neuro Product Information](https://www.insightec.com/solutions/exablate-neuro)
[CarThera - SonoCloud Technology](https://www.carthera.com/)
[Shoesmith JH et al., Blood-brain barrier opening with focused ultrasound: Safety and efficacy in Alzheimer's disease (2022)](https://doi.org/10.1016/j.addr.2022.114562)
[Lipsman N et al., Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound (2018)](https://doi.org/10.1038/s41467-018-04529-0)
[Rezai AR et al., Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound (2020)](https://doi.org/10.1073/pnas.1918650117)
[D'Haese PF et al., β-Amyloid plaque reduction with focused ultrasound in patients with Alzheimer's disease (2022)](https://doi.org/10.3171/2021.9.JNS212241)
[Carpentier A et al., Clinical trial of blood-brain barrier disruption by pulsed ultrasound (2016)](https://doi.org/10.1126/scitranslmed.aaf6089)Pathway Diagram
The following diagram shows the key molecular relationships involving ad-focused-ultrasound-bbb-opening-companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)